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ABSTRACT
ObjeCtive
To examine the risk of community acquired pneumonia 
before and after prescription of proton pump inhibitor 
(PPI) and assess whether unmeasured confounding 
explains this association.
Design
Cohort study and self controlled case series.
setting
Clinical Practice Research Datalink (1990 to 2013) in UK.
PartiCiPants
Adult patients with a new prescription for a PPI 
individually matched with controls.
Main OutCOMe Measures
Association of community acquired pneumonia with 
PPI prescription estimated by three methods: a 
multivariable Cox model comparing risk in PPI exposed 
patients with controls, corrected for potential 
confounders; a self controlled case series; and a prior 
event rate ratio (PERR) analysis over the 12 month 
periods before and after the first PPI prescription.
results
160 000 new PPI users were examined. The adjusted 
Cox regression showed a risk of community acquired 
pneumonia 1.67 (95% confidence interval 1.55 to 1.79) 
times higher for patients exposed to PPI than for 
controls. In the self controlled case series, among 
48 451 PPI exposed patients with a record of 
community acquired pneumonia, the incidence rate 
ratio was 1.19 (95% confidence interval 1.14 to 1.25) in 
the 30 days after PPI prescription but was higher in the 
30 days before a PPI prescription (1.92, 1.84 to 2.00). 
The Cox regressions for prior event rate ratio similarly 
showed a greater increase in community acquired 
pneumonia in the year before than the year after PPI 
prescription, such that the analysis showed a reduced 
relative risk of pneumonia associated with PPI use 
(prior event rate ratio 0.91, 95% confidence interval 
0.83 to 0.99).
COnClusiOn
The association between the use of PPIs and risk of 
community acquired pneumonia is likely to be due 
entirely to confounding factors.
Introduction
Proton pump inhibitors (PPIs) have become the corner-
stone of medical treatment for acid related gastrointes-
tinal disorders. The widespread use of PPI treatment in 
clinical settings means that even if the health risks 
associated with their use are modest, they could have a 
substantial effect on a large number of patients.1 2  One 
of the adverse outcomes associated with PPI use that 
has attracted a considerable amount of attention in 
existing research is the possible increase in the risk of 
pneumonia.3-7  This association has been hypothesised 
to be related to bacterial overgrowth and colonisation 
as a result of alteration of the acidity of the stomach.4 5 
Meta-analyses of randomised controlled trials have 
shown that the use of PPIs to prevent stress ulcers may 
increase the risk of hospital acquired pneumonia in 
critically ill patients.8 9  However, in the context of com-
munity acquired pneumonia, which is a common cause 
of morbidity and mortality especially among older peo-
ple and those with other medical comorbidities,10  this 
link has been inconsistent in previous observational 
studies.11-16  These studies have been criticised for a lack 
of control for unmeasured confounding (such as 
patients’ characteristics and comorbidities)17  and bias 
(such as confounding by indication)18 that may impair 
the significance of the association.
In the absence of data from randomised controlled 
trials, the variation in the risk of community acquired 
pneumonia among PPI users compared with non-users 
in previous studies may be attributable to differences 
between the groups in known and unknown risk fac-
tors. Advances in analytical techniques may enhance 
the validity of the results of observational studies by 
attempting to mitigate some of the effects of hidden 
confounding. We therefore aimed to assess whether 
confounding explains the association between the use 
of PPIs and the risk of community acquired pneumonia 
by using appropriate analytical techniques on observa-
tional data.
Methods
Data source
We used the Clinical Practice Research Datalink 
(CPRD), a large UK based electronic database of  primary 
care records (www.cprd.com).19  CPRD has been exten-
sively used and validated for pharmacoepidemiology 
research.19-21  The database contains anonymised infor-
mation about patients that encompasses medical diag-
noses, prescriptions, investigations, and referrals to 
WhAT IS AlReAdy knoWn on ThIS TopIC
Studies have suggested that patients who are treated with proton pump inhibitors 
(PPIs) have an increased risk of developing community acquired pneumonia
Potential confounders and bias may impair the interpretation of the association 
that has been observed in these studies
WhAT ThIS STudy AddS
The crude association between PPI prescriptions and an increased rate in community 
acquired pneumonia could be explained by an underlying increased risk of pneumonia
The confounding factors present before PPI use, rather than PPI use itself, were the 
main contributors to an increased rate of community acquired pneumonia in 
patients receiving PPIs
doi: 10.1136/bmj.i5813 | BMJ 2016;355:i5813 | the bmj
RESEARCH
2
secondary care. More than 50% of the practices that 
include their records in the CPRD have consented to 
their patients’ records being linked with Hospital Epi-
sode Statistics data and Office for National Statistics 
mortality data.19  Hospital Episode Statistics data con-
tain information on all patients who have been admit-
ted to hospital, together with information about the 
primary and secondary causes of each episode of inpa-
tient care (with diagnosis coded using ICD-10 (interna-
tional classification of diseases, 10th revision)), type of 
admission, procedure performed, length of stay, and 
discharge status.22
study population
The study population included people aged 18 years or 
over and registered in the CPRD from 1 January 1990 to 
1 August 2013. Patients had to have at least one year of 
registration on CPRD after the later of the date of cur-
rent registration and the date the practice became “up 
to standard” on CPRD,21  as well as an “acceptable” reg-
istration status as defined by CPRD.21 We identified an 
exposed cohort from this source population as a ran-
dom sample of 160 000 people who received a first pre-
scription for a PPI in CPRD at least one year after they 
started contributing data during the study period (that 
is, new users). We calculated the duration of each PPI 
prescription by using the number of treatment days 
recorded by the general practitioner or dividing the 
total prescription quantity by the numeric daily dose 
prescribed for each prescription.
We also identified a subset of patients with linked 
Hospital Episode Statistics/Office for National Statistics 
data within the study population and selected these 
patients to improve the ascertainment of the outcome of 
this study (that is, community acquired pneumonia). 
For this subset, we looked specifically at patients with 
more severe community acquired pneumonia requiring 
hospital admission by limiting the definition of pneu-
monia to those coded within Hospital Episode Statis-
tics/Office for National Statistics data. We also modified 
the follow-up period to be consistent with the linkage 
coverage period (from January 1998 to January 2012).
Outcome
We defined community acquired pneumonia in the 
CPRD by the presence of a Read code for this diagnosis 
(list of codes available on request). The list included 
codes for chest infection and lower respiratory tract 
infection to ensure that all cases of community acquired 
pneumonia categorised in this way were captured. We 
refer to this as our broad primary care definition and 
also used a narrow primary care definition eliminating 
codes not specific for pneumonia. We regarded pneu-
monia diagnoses recorded less than 84 days apart as 
the same event, as we considered 84 days to be suffi-
cient for the clinical condition and lung function to 
have returned to the baseline state.23 24 For patients with 
Hospital Episode Statistics/Office for National Statistics 
linked data, we identified episodes of hospital admis-
sion that were allocated a primary diagnosis of commu-
nity acquired pneumonia or a death certificate that was 
issued between March 1997 and April 2012 on which 
pneumonia was listed as a contributing or underlying 
cause of death (on the basis of ICD coding).
study design
We used self controlled case series and cohort study 
designs in this study.
Self controlled case series study
The self controlled case series analysis method is a type 
of cohort study in which relative risk is based on within 
person comparisons between exposed and unexposed 
observation time, so only exposed patients with events 
can be included.25  The advantage of this design is that 
the influence of between person confounding will be 
eliminated.25 26  From the cohort exposed to PPIs, we 
selected all the cases with a recorded diagnosis of com-
munity acquired pneumonia. We considered the expo-
sure to PPIs to begin on the date of PPI prescription and 
to end after its calculated duration including any con-
secutive prescriptions, plus an additional 30 day wash-
out period. We then divided the observation time into 
risk windows for each person: 30 days before starting 
the first PPI prescription; 0-30 days after starting the 
first PPI prescription; and the remaining exposed 
period with the post-exposure 30 day period. The base-
line (unexposed) period consisted of all observation 
times for which no PPI prescription was issued within 
the study period (fig 1). The purpose of the additional 30 
day period before the first prescription was to assess 
whether any increase in community acquired pneumo-
nia rate was associated with an acute event that might 
have precipitated the PPI prescription.
Baseline period (no PPI prescription)
Start of
observation
period
End of
observation
period
First PPI
prescription
End of PPI
course
Start of second
PPI course
Pre-exposure period (30 days before rst PPI prescription)
30 days exposure period (30 days aer rst PPI prescription)
Remaining exposure period
Fig 1 | illustration of self controlled case series method showing division of time of each person included in this analysis to 
assess incidence of community acquired pneumonia in relation to prescription for proton pump inhibitor (PPi). events of 
pneumonia can occur during baseline or exposure period
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Cohort study
For this study design, we individually matched the 
exposed patients one to one by age (within 5 years), sex, 
and year of prescription with an unexposed cohort who 
had never received a PPI prescription. We required these 
unexposed controls also to have been contributing data 
for at least one year before their matched patient’s first 
prescription. The following potential confounders were 
extracted and evaluated from the CPRD primary care 
record, both for all CPRD patients and for the subset of 
patients with Hospital Episode Statistics/Office for 
National Statistics linked data: smoking status (catego-
rised into smoker, never smoked, or missing), alcohol use 
(never drinker, ever drinker, or missing), number of visits 
to the general practitioner in the year before the PPI pre-
scription (five visits or fewer, or more than five visits), 
immunosuppression (defined as chemotherapy treatment 
within the previous six months, systemic high dose steroid 
treatment for three months, receipt of certain immunosup-
pressive drugs, having a solid organ transplant with any 
anti-rejection drugs in the previous year, or having a diag-
nosis of HIV infection27 ), and comorbidities categorised 
on the basis of the Charlson index score.28 We assessed 
comorbidities by using the entire patient record before the 
first PPI prescription date for the exposed cohort or the 
matched date for the unexposed cohort. We also included 
prescriptions of systemic corticosteroid and opioid (within 
90 days before the prescription or matched date). In addi-
tion, we included data on the socioeconomic status mea-
sured using the Index of Multiple Deprivation 2007.
statistical analyses
We calculated descriptive summary statistics for the 
study population by exposure status. We then did the 
analyses below, both for all CPRD patients and for the 
subset of patients with Hospital Episode Statistics/
Office for National Statistics linked data. For each anal-
ysis, we present results for our three different defini-
tions of community acquired pneumonia (broad 
primary care definition, narrow primary care definition, 
and hospital and mortality records based definition). 
We used the same cohort across the study designs to 
avoid using multiple cohorts, because this may cause 
confusion when comparing the study results. We used 
Stata 12 for all statistical analyses.
Self controlled case series analysis
We used conditional Poisson regression models with 
fixed effects to calculate the incidence rate ratio com-
paring the incidence rate of community acquired pneu-
monia during the exposure period with the incidence 
rate during the baseline period, with adjustment for age 
(5 year bands).25 26 This allows inclusion of multiple 
events of pneumonia during the observation period and 
adjusts for the correlations within individuals. Thus, 
the data were expanded to panel data, so that each row 
corresponded to a single time interval for each case. We 
then identified the numbers of events that occurred 
within each interval. We excluded person time after the 
pneumonia event until the day after the date of resolu-
tion of pneumonia, because no additional events could 
occur until the current pneumonia had resolved.
Cohort study
We did two analyses using this study design: a multi-
variable Cox proportional hazards analysis and a prior 
event rate ratio analysis.29-31
In the adjusted Cox regression analysis, we considered 
the first occurrence of community acquired pneumonia 
after the index date. We used Cox proportional hazards 
modelling to estimate the hazard ratio for pneumonia in 
people receiving PPIs, adjusted for potential confound-
ers, with 95% confidence intervals. We followed the 
cohorts from the date of their first PPI prescription until 
the earliest of the pneumonia event date, prescription end 
date, or study end date (this was the earliest date of the 
following: end of observation time (1 August 2013), date of 
death, date transferred to a different practice, or last date 
of data collection from practice). We tested the validity of 
the proportional hazards assumption by plotting log-mi-
nus-log survival curves and carrying out Schoenfeld tests. 
We included each potential confounder in the model if 
they modified the hazard ratio by more than 10%. We cat-
egorised missing data into a separate category.
The prior event rate ratio adjustment method has 
recently been proposed as a means of reducing the bias 
that results from residual confounding.29-31  This method 
requires that both exposed and unexposed cohorts did 
not receive the study drug before the index date—that is, 
the date at which the exposed cohort first received the 
prescription and the matched date for the unexposed 
patients. The method relies on a before and after design 
and is based on the assumption that the differences in 
outcomes between exposed and unexposed patients 
before receiving the treatment reflect the combined effect 
of confounders independently of any effect of the study 
drug.29 31  The prior event rate ratio is estimated by the 
ratio of two unadjusted hazard ratios: the unadjusted 
hazard ratio for community acquired pneumonia during 
the year after initial PPI prescription for the exposed 
group versus the unexposed group (HR.post) and the 
unadjusted hazard ratio for community acquired pneu-
monia before the PPI prescription of the exposed versus 
the unexposed people (HR.prior)—prior event rate ratio 
adjusted hazard ratio=HR.post/HR.prior (fig 2 ). There-
fore, the prior event rate ratio provides an estimate of the 
effect the drug exposure had on the hazard adjusted for 
Follow-up time
PPI exposure
Hazard ratio prior reflects
dierences in pneumonia risk
Hazard ratio post reflects dierences
in pneumonia risk and PPI eect
Post-exposure periodPrior-exposure period
Exposed patients
Non-exposed patients
Fig 2 | Prior event rate ratio adjustment method. Prior period means time before index date 
(proton pump inhibitor (PPi) prescription date for exposed cohort and matched date for 
unexposed patients); post period means time after PPi exposure
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confounding.31  The follow-up of patients in the year after 
initial PPI prescription ran from the date of their first PPI 
prescription until the earliest of the anniversary of that 
date, the occurrence of a pneumonia event, or the study 
end date. For the year before the initial PPI prescription, 
patients were followed from the date one year before 
starting the PPI until the earliest of a pneumonia event or 
the start of the PPI. We obtained the 95% confidence 
intervals of the prior event rate ratio by bootstrapping.29 31
sensitivity analyses
As with any statistical method, several assumptions must 
be met for both the self controlled case series analysis and 
prior event rate ratio analysis methods to be considered 
reliable. We did sensitivity analyses to assess the possibil-
ity that these assumptions had been violated. For the self 
controlled case series, the first assumption is that the 
occurrence of recurrent outcome events must be indepen-
dent—that is, the occurrence of one event must not alter 
the probability of a subsequent event occurring.25  We did 
a sensitivity analysis restricted to the first event of commu-
nity acquired pneumonia during the observation period to 
assess this assumption. The second assumption of the self 
controlled case series, as well as for prior event rate ratio, 
was that the occurrence of one event should not alter the 
probability of subsequent exposure.25 31  Although pneu-
monia is not a recognised indication, caution, or contrain-
dication for the use of PPIs, it is likely that hospital 
admission could lead to the prescription of a PPI.32  To 
account for this, we did an analysis that was limited to 
new users of PPIs who had not been admitted to hospital 
in the 60 days before the first PPI course. The third 
assumption is that mortality subsequent to an event 
should not alter the probability of subsequent expo-
sure.26 31  For the self controlled case series analysis, we did 
a sensitivity analysis that excluded people who had died 
within 90 days of the recorded community acquired pneu-
monia, as such cases could have used PPIs only before 
community acquired pneumonia and not afterwards. Sim-
ilarly, for the prior event rate ratio analysis, we did sensi-
tivity analysis restricted to non-fatal pneumonia on the 
basis that it would be impossible for fatal pneumonia 
cases to occur in the one year before the first PPI prescrip-
tion, whereas fatal pneumonia could occur afterwards. 
Also, we carried out a sensitivity analysis that was limited 
to cases before the point at which the first large population 
based study suggesting an association was published in a 
specialised medical journal,11 to minimise the risk that 
knowledge of patients’ PPI use could affect diagnosis of 
pneumonia or that previous pneumonia events could 
affect the physician’s decision to prescribe a PPI.
For the Cox regression analysis and prior event rate 
ratio, we did a sensitivity analysis restricted to people 
over the age of 65 years (who are eligible to receive free 
prescriptions and therefore were less likely to purchase 
over the counter drugs) and to the time period before 
the availability of the over counter PPIs in the UK.33
sample size calculation
We used the stpower Cox command to calculate the 
minimum number of events needed to detect a hazard 
ratio of 1.1 with 90% power and α=0.05. With an esti-
mated incidence rate of 0.6 per 100 unexposed person 
years,11 23 we estimated that 160 000 patients were 
needed assuming an average five year follow-up period 
for each patient and constant pneumonia risk over cal-
endar time. This study population of 160 000 PPI 
exposed patients, therefore, was randomly sampled 
from the whole CPRD population according to the 
power calculation outlined above.
Patient involvement
No patients were involved in the development of the 
research question or the outcome measures. No patients 
were involved in developing plans for recruitment, 
design, or implementation of the study, nor were they 
asked to advice on interpretation or writing up of 
results. There are no plans to disseminate the results of 
the research to study participants.
Results
We identified 160 000 new users of PPIs during the 
study period who were matched individually to an 
equal number of non-PPI exposed patients. The mean 
age at entry to the study was 56 (SD 16) years for both 
exposed and unexposed cohorts, and 55% (n=88 455) of 
each cohort were women. Compared with unexposed 
patients, those prescribed PPIs were more likely to have 
a history of smoking (42.9% v 33.7% of their matched 
controls) and alcohol use (29.1% v 23.9%); they also had 
a higher burden of comorbidity and used more cortico-
steroids and opioids (table 1 ). Hospital Episode Statis-
tics/Office for National Statistics linked information 
was available for 257 886 of the patients, whose 
 characteristics were largely similar to those of the com-
plete cohort (table 1). Most patients used PPIs for a 
short period, with a median duration of 28 (interquar-
tile range 28-76) days.
Cox regression analysis
In this analysis, the exposed patients had an 
increased hazard of pneumonia defined by each of the 
three definitions of community acquired pneumonia. 
Hazard ratios were greater when we defined commu-
nity acquired pneumonia more narrowly, with unad-
justed hazard ratios of 5.44 (95% confidence interval 
4.23 to 6.99) and 4.76 (4.12 to 5.49) when we used nar-
row primary care definitions and hospital/mortality 
records based definitions, respectively (table 2 ). After 
adjustment, the hazard of pneumonia by our broad 
primary care definition fell to 1.67 (1.55 to 1.79) times 
that of controls in PPI exposed patients, and the haz-
ard ratios were similarly reduced by adjustment for 
confounding when our narrower primary care defini-
tions of pneumonia were used (table 2 ). In each case, 
however, we found a statistically significant excess of 
pneumonia in the exposed cohort. As the Charlson’s 
index was developed to predict mortality and not 
morbidity, we carried out a separate analysis adjusted 
for individual important potential confounders for 
pneumonia that resulted in a slight reduction in the 
hazard ratio (table 2).
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self controlled case series
From the exposed cohort, we identified 48 451 PPI 
exposed patients in CPRD with a record of at least one 
community acquired pneumonia (broad primary care 
definition), with a mean age of 60 (SD 16) years, and 
5582 patients in Hospital Episode Statistics linked data 
who had a record of pneumonia related to hospital 
admission or death, with mean age of 70 (SD 14) years.
Table 3  shows the incidence rate ratios for the differ-
ent risk windows and pneumonia definitions. Using our 
broad definition, the incidence rate ratio for pneumonia 
among PPI users was 1.19 (1.14 to 1.25) for 30 days after 
PPI prescription and 1.49 (1.46 to 1.52) for the remaining 
exposure period compared with the baseline period 
(table 3 ). The incidence rate ratio for the 30 days before 
exposure was even higher at 1.92 (1.84 to 2.00). As for 
the Cox regression, differences in ratios were higher for 
the more narrow definition of pneumonia (table 3).
Prior event rate ratio analysis
The rate of pneumonia for the exposed patients was 
similar before a PPI prescription (62.1 per 1000 person 
years of follow-up) to the rate after a PPI prescription 
(61.4 per 1000 person years of follow-up), whereas the 
rate of pneumonia in unexposed patients increased 
over the study period (table 4 ). The prior event rate 
table 1 | Demographic and clinical characteristics of study population included in cohort 
study by exposure status at cohort entry into study period, for all CPrD patients and for 
subset of patients with Hes-Ons linked data. values are numbers (percentages)
Characteristic
Complete cohorts 
(n=320 000)
Hes-Ons linked patients 
(n=257 886)
unexposed 
(n=160 000)
exposed 
(n=160 000)
unexposed 
(n=128 943)
exposed 
(n=128 943)
Smoking:
 Never smoked 59 581 (37.2) 57 805 (36.1) 47 243 (36.7) 45 757 (35.5)
 Smoker 53 889 (33.7) 68 612 (42.9) 43 633 (33.8) 55 935 (43.4)
 Missing 46 530 (29.1) 33 583 (21.0) 38 067 (29.5) 27 251 (21.1)
Alcohol use:
 Never drinker 48 961 (30.6) 51 747 (32.3) 40 394 (31.3) 42 716 (33.1)
 Ever drinker 38 292 (23.9) 46 524 (29.1) 29 364 (22.8) 36 246 (28.1)
 Missing 72 747 (45.5) 61 729 (38.6) 59 185 (45.9) 49 981 (38.8)
Index of Multiple Deprivation fifths*:
 Unavailable 4833 (3.0) 4333 (2.7) 24 (0.02) 26 (0.02)
 1 (least deprived) 41 096 (25.7) 36 149 (22.6) 34 359 (26.6) 29 987 (23.3)
 2 37 827 (23.6) 36 504 (22.8) 31 588 (24.5) 30 236 (23.4)
 3 30 651 (19.2) 30 904 (19.3) 25 464 (19.8) 25 739 (20.0)
 4 27 332 (17.1) 30 002 (18.8) 22 542 (17.5) 24 867 (19.3)
 5 (most deprived) 18 261 (11.4) 22 108 (13.8) 14 966 (11.6) 18 088 (14.0)
Charlson comorbidity index score:
 0 99 492 (62.2) 72 290 (45.2) 79 978 (62.0) 58 048 (45.0)
 1-2 48 287 (30.2) 63 461 (39.7) 39 124 (30.4) 51 098 (39.6)
 3-4 9510 (5.9) 17 494 (10.9) 7775 (6.0) 14 413 (11.2)
  >5 2711 (1.7) 6755 (4.2) 2066 (1.6) 5384 (4.2)
No of general practitioner visits:
 ≤5 87 286 (54.5) 37 605 (23.5) 69 788 (54.1) 29 582 (22.9)
 >5 72 714 (45.4) 122 395 (76.5) 59 155 (45.9) 99 361 (77.1)
Immunosuppression† 4882 (3.0) 16 609 (10.3) 3866 (3.0) 13 723 (10.6)
Non-topical corticosteroid use 5832 (3.6) 15 990 (9.9) 4814 (3.7) 13 221 (10.2)
Opioid prescriptions 1557 (0.9) 9469 (5.9) 1261 (0.9) 7809 (6.0)
CPRD=Clinical Practice Research Datalink; HES=Hospital Episode Statistics; ONS=Office for National Statistics.
*Socioeconomic status is based on Index of Multiple Deprivation; values are percentage of people who had 
deprivation status available.
†Immunosuppressed patients defined according to criteria to contraindicate vaccination.27
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ratio for pneumonia (broad primary care definition) 
was 0.91 (0.83 to 0.99) on the basis of an unadjusted 
post-PPI hazard ratio of 2.06 (1.98 to 2.14) divided by an 
unadjusted prior-PPI hazard ratio of 2.26 (2.18 to 2.35). 
Similarly, the prior event rate ratio for pneumonia in 
Hospital Episode Statistics/Office for National Statistics 
subset was 0.74 (0.69 to 0.97) (table 4).
sensitivity analysis
For the self controlled case series analysis, restricting 
the primary analysis to only the first event recorded 
resulted in reductions in the observed rate ratios of 
pneumonia after PPI prescriptions, whereas no change 
was seen in the risk of pneumonia before the PPI pre-
scription (supplementary table A). After exclusion of 
the 20% of patients in the self controlled case series 
analysis who had been admitted to hospital before their 
first PPI prescription, the incidence rate ratio for com-
munity acquired pneumonia (using our broad primary 
care definition of pneumonia) was very little changed 
from that of our primary analysis (supplementary table 
B). Around 5% of patients died within 90 days of the 
date of diagnosis of pneumonia, and the results of the 
analysis excluding these patients showed a reduction in 
the incidence rate ratio for pneumonia for 30 days after 
PPI prescription and for the remaining exposure period 
(supplementary table C).
For the prior event rate ratio method, both of the 
analyses to test for a possible violation of the underly-
ing assumption concerning the effect of hospital admis-
sion on the probability of subsequent PPI exposure and 
the effect of mortality produced similar results to the 
primary analysis (supplementary tables D and E). The 
results from the remaining sensitivity analyses were 
very similar to those from the whole population for Cox 
regression and prior event rate ratio analyses (supple-
mentary tables F-J).
discussion
This study has shown that a crude association exists 
between PPI prescriptions and an increased rate of 
community acquired pneumonia, but that this is 
explained by an underlying increased risk of pneumo-
nia in patients preceding a PPI prescription. Further-
more, after adjustment for confounding and changes 
over time, the relative rate of community acquired 
pneumonia actually fell after PPI prescriptions.
strengths and limitations of study
A major strength of this study is that we have used rou-
tinely collected general practice records to conduct it. 
This provides for an unbiased selection of both the 
exposed and control cohorts and reduces the opportu-
nity for information bias (as both PPI prescription and 
pneumonia diagnosis were prospectively collected 
independently). In addition, as the base population is 
representative of the UK general population, our results 
are likely to be generalisable at least to the UK popula-
tion and to other similar populations.21 However, the 
generalisability of self controlled case series analysis is 
limited, as patients who are included may have a 
 different underlying risk of community acquired pneu-
monia than the baseline population.
A further strength is that data were available relating 
to several potential confounders, allowing us to control 
for the effects of these in the Cox regression models. 
However, missing data with respect to smoking and 
alcohol use show a risk of residual confounding by 
these factors in addition to unmeasured confounding. 
An important methodological strength therefore is that 
we have used two analytical methods to mitigate the 
effect of confounders that are difficult to measure or 
incompletely measured.
We used the same patients as their own control in the 
case series method to minimise confounding due to 
patients’ characteristics and comorbidities. The condi-
tional Poisson regression model represented an effec-
tive choice in our analysis of recurrent events of 
community acquired pneumonia because previous 
studies have shown it to be effective in terms of the 
over-dispersion and autocorrelation of panel data.34 35 
Also, we examined the key assumptions underlying the 
self controlled case series method by looking for evi-
dence that the occurrence of pneumonia does not alter 
the risk of subsequent PPI prescription. Excluding from 
the main analyses those patients who had been admit-
ted to hospital or died after pneumonia events had no 
substantial effect on the results. However, as this 
method adjusts for a fixed relative difference in con-
founders between the exposed and unexposed cohorts, 
it does not reduce confounding due to factors that may 
vary over time differently between the exposed and 
unexposed people.
We also attempted to overcome the limitations of pre-
vious observational work by using a newer analytical 
technique, prior event rate ratio, which has been 
 proposed as a method of controlling for unmeasured 
time-fixed confounding.29 31 With this method, we were 
able to adjust both for the underlying increased risk of 
pneumonia in patients who were treated with PPIs (that 
confounded a standard Cox regression) and for changes 
in pneumonia incidence over time (that may have con-
founded the case series analysis). Although prior event 
rate ratio methods offer a promising approach to over-
come biases that can arise in observational studies, in 
practice we cannot exclude all situations in which pre-
vious events might influence future treatments. How-
ever, we attempted to assess the potential biases 
carefully by examining the possible causes of violations 
of the prior event rate ratio assumptions via either hos-
pital admission, death, or the publication of studies of 
pneumonia risks influencing PPI prescriptions, and we 
found no evidence to suggest that prior event rate ratio 
represented an inappropriate analytical technique in 
our study.
One potential limitation is the possibility of error in 
our assessment of exposure, as CPRD data includes 
only information about the prescriptions and does not 
prove that the prescribed drug has been taken. This 
could lead to exposure misclassification, especially in 
the case of patients who took PPI intermittently. How-
ever, as PPIs are initially prescribed for symptom 
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 control, this may not lead to a large overestimation. 
Additionally, previous studies reported that relying on 
prescription information as a surrogate for PPI use is 
unlikely to introduce significant misclassification.14
Although the information contained in the CPRD has 
been validated for a wide range of diagnoses, including 
other respiratory disease36 —and in particular the diag-
nosis of pneumonia in the linked CPRD-Hospital Epi-
sode Statistics data has been examined10—general 
practitioners often diagnose community acquired 
pneumonia without a radiograph, which may lead to 
misclassification between this and other conditions (for 
example, chest infection or chronic respiratory tract 
infection). We tried to reduce the effect of such misclas-
sification by using more specific diagnostic codes for 
community acquired pneumonia (using our narrow 
definition) and by an analysis limited to patients with 
hospital or death certificate diagnoses in the sensitivity 
analyses.
Comparison with existing literature
Many studies have examined the association between 
PPI treatment and the risk of community acquired 
pneumonia. Early observational studies showed that 
using PPIs might be associated with an increased risk of 
community acquired pneumonia.11-13  Further studies 
suggested that a dose-response relation supported cau-
sality of the association,11 16  and yet others argued that 
a temporarily increased risk suggested the presence of 
protopathic bias.17 18  There have also been studies 
including a retrospective analysis of the original safety 
data from several randomised clinical trials of esome-
prazole (one specific PPI),37  which failed to show any 
such association despite statistical adjustment for con-
founders.14 15  Concern was amplified, however, by 
 findings from meta-analyses based on these observa-
tional studies that showed that the risk of community 
acquired pneumonia was 34-49% higher among 
patients who used PPIs than it was among non-users, 
with a temporal relation soon after the start of the PPI 
treatment.5 7 Thus, evidence linking PPI treatment to 
the risk of community acquired pneumonia remains 
inconclusive.
We have examined the association of PPI use and 
community acquired pneumonia and assessed whether 
residual and time-fixed confounding explains this asso-
ciation. The results of the adjusted Cox regression model 
in this study did not differ from either the early observa-
tional studies or previous studies that used CPRD data 
and found a similar association. However, self con-
trolled case series analysis shows that this risk predates 
prescription, and the prior event rate ratio analysis sug-
gests that the significant association observed can be 
attributed to confounding. Previous studies have 
reported that the highest risk of pneumonia occurs in 
the first 30 days, whereas we observed an incidence rate 
ratio of 1.19 in the 30 days after PPI prescription and 1.49 
for the remaining exposure period. This apparent con-
tradiction may be explained by differences in the sub-
populations of patients taking long term and short term 
PPIs; as most courses in our data were short term, the 
initial 30 days will primarily reflect these patients 
whereas the later period will be long term users.
Our findings from the prior event rate ratio analysis 
are comparable to those of a recent study that analysed 
the pooled adverse event data related to respiratory 
tract infection reported in randomised double blind 
clinical studies that were specific to esomeprazole.38 
The reported relative risk for pneumonia in patients 
receiving esomeprazole compared with the placebo in 
that study was 0.66 (95% confidence interval 0.36 to 
1.22).38 Although the populations recruited to ran-
domised controlled trials are often not typical of those 
receiving PPIs in general practice, our results suggest 
that these findings may well be widely generalisable. 
We believe that this comparison is also an important 
validation of the prior event rate ratio method, which 
has had limited use previously.
Conclusion
Our results indicate that no strong evidence exists to 
support the association between the use of PPIs and an 
increase in the risk of community acquired pneumonia. 
Patients who are treated with PPIs have an underlying 
risk of community acquired pneumonia before receiv-
ing the PPI prescription. Therefore, patients’ character-
istics, comorbidity, and severity of gastro-oesophageal 
reflex disease were probably the main contributors to 
the increased risk of pneumonia observed in patients 
who received PPIs.17 18
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